Generic versions of Bristol Myers Squibb’s top-selling cancer drug Revlimid (lenalidomide) have been launched across Europe today, with Sandoz and Stada among the leading generics firms to have confirmed the introduction of their versions in numerous European markets.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?